Literature DB >> 21489624

F317L BCR-ABL1 kinase domain mutation associated with a sustained major molecular response in a CML patient on dasatinib.

Anthony A Oyekunle, Fausto Castagnetti, Gabriele Gugliotta, Simona Soverini, Michele Baccarani, Gianantonio Rosti.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21489624     DOI： 10.1016/j.leukres.2011.03.021

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


× No keyword cloud information.
  3 in total

Review 1.  CXCL12/CXCR4 axis in the pathogenesis of acute lymphoblastic leukemia (ALL): a possible therapeutic target.

Authors:  Aparecida de Lourdes Perim; Marla Karine Amarante; Roberta Losi Guembarovski; Carlos Eduardo Coral de Oliveira; Maria Angelica Ehara Watanabe
Journal:  Cell Mol Life Sci       Date:  2015-01-09       Impact factor: 9.261

2.  Successful treatment of Philadelphia chromosome-positive mixed phenotype acute leukemia by appropriate alternation of second-generation tyrosine kinase inhibitors according to BCR-ABL1 mutation status.

Authors:  Chika Kawajiri; Hiroaki Tanaka; Shinichiro Hashimoto; Yusuke Takeda; Shio Sakai; Toshiyuki Takagi; Masahiro Takeuchi; Chikako Ohwada; Emiko Sakaida; Naomi Shimizu; Chiaki Nakaseko
Journal:  Int J Hematol       Date:  2014-02-15       Impact factor: 2.490

3.  Dasatinib May Override F317L BCR-ABL Kinase Domain Mutation in Patients with Chronic Myeloid Leukemia.

Authors:  Ahmet Emre Eşkazan; Teoman Soysal
Journal:  Turk J Haematol       Date:  2013-06-05       Impact factor: 1.831
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.